These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 30131292)

  • 1. The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era.
    Chen YW; Ornstein MC; Wood LS; Allman KD; Martin A; Beach J; Gilligan T; Garcia JA; Rini BI
    Urol Oncol; 2018 Oct; 36(10):470.e19-470.e29. PubMed ID: 30131292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer.
    Chen YW; Mahal BA; Muralidhar V; Nezolosky M; Beard CJ; Den RB; Feng FY; Hoffman KE; Martin NE; Orio PF; Nguyen PL
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(4):683-90. PubMed ID: 26972640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Facility Volume and Survival in Patients with Metastatic Renal Cell Carcinoma: A Registry-based Analysis.
    Joshi SS; Handorf EA; Zibelman M; Plimack ER; Uzzo RG; Kutikov A; Smaldone MC; Geynisman DM
    Eur Urol; 2018 Sep; 74(3):387-393. PubMed ID: 29880274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
    Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
    Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors, utilization patterns, and overall survival of patients undergoing metastasectomy for metastatic renal cell carcinoma in the era of targeted therapy.
    Sun M; Meyer CP; Karam JA; de Velasco G; Chang SL; Pal SK; Trinh QD; Choueiri TK
    Eur J Surg Oncol; 2018 Sep; 44(9):1439-1445. PubMed ID: 29935840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Initial Surgery vs Initial Systemic Therapy for Metastatic Kidney Cancer in the Targeted Therapy Era: Analysis of a Population-based Cohort.
    Macleod LC; Odisho AY; Tykodi SS; Holt SK; Harper JD; Gore JL
    Urology; 2018 Mar; 113():146-152. PubMed ID: 29174942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is Treatment at a High-volume Center Associated with an Improved Survival for Primary Malignant Bone Tumors?
    Malik AT; Alexander JH; Khan SN; Scharschmidt TJ
    Clin Orthop Relat Res; 2020 Mar; 478(3):631-642. PubMed ID: 31714413
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of patients undergoing cytoreductive surgery for metastatic renal cell carcinoma in the targeted-therapy era.
    Abern MR; Scosyrev E; Tsivian M; Messing EM; Polascik TJ; Dudek AZ
    Anticancer Res; 2014 May; 34(5):2405-11. PubMed ID: 24778051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.
    Marchioni M; Bandini M; Pompe RS; Tian Z; Martel T; Kapoor A; Cindolo L; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
    Int Urol Nephrol; 2017 Dec; 49(12):2143-2149. PubMed ID: 28932952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival Analyses of Patients With Metastatic Renal Cancer Treated With Targeted Therapy With or Without Cytoreductive Nephrectomy: A National Cancer Data Base Study.
    Hanna N; Sun M; Meyer CP; Nguyen PL; Pal SK; Chang SL; de Velasco G; Trinh QD; Choueiri TK
    J Clin Oncol; 2016 Sep; 34(27):3267-75. PubMed ID: 27325852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Timing of brain metastases development in metastatic renal cell cancer patients treated with targeted therapies and survival outcomes: An Australian multicenter study.
    Ha FJ; Spain L; Dowling A; Kwan EM; Pezaro C; Day D; Chia PL; Tran B; Pook D; Weickhardt AJ
    Asia Pac J Clin Oncol; 2019 Oct; 15(5):e97-e102. PubMed ID: 30701671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the effect of treatment at high-volume hospitals on overall survival following cytoreductive nephrectomy.
    Berg S; Cole AP; Fletcher SA; Pucheril D; Nabi J; Lipsitz SR; Chang SL; Sun M; Noldus J; Harshman LC; Choueiri TK; Trinh QD
    Urol Oncol; 2018 Sep; 36(9):400.e15-400.e22. PubMed ID: 30274640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry.
    de Groot S; Redekop WK; Sleijfer S; Oosterwijk E; Bex A; Kiemeney LA; Uyl-de Groot CA
    Urology; 2016 Sep; 95():121-7. PubMed ID: 27179773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era.
    Macleod LC; Tykodi SS; Holt SK; Wright JL; Lin DW; Tretiakova MS; True LD; Gore JL
    Urology; 2015 Aug; 86(2):262-8. PubMed ID: 26199164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disease-specific survival in de novo metastatic renal cell carcinoma in the cytokine and targeted therapy era.
    Pal SK; Nelson RA; Vogelzang N
    PLoS One; 2013; 8(5):e63341. PubMed ID: 23658823
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Facility Volume and Survival in Nasopharyngeal Carcinoma.
    Yoshida EJ; Luu M; David JM; Kim S; Mita A; Scher K; Shiao SL; Tighiouart M; Lee NY; Ho AS; Zumsteg ZS
    Int J Radiat Oncol Biol Phys; 2018 Feb; 100(2):408-417. PubMed ID: 29100787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association Between Treatment Facility Volume and Mortality of Patients With Multiple Myeloma.
    Go RS; Bartley AC; Crowson CS; Shah ND; Habermann EB; Holton SJ; Holmes DR
    J Clin Oncol; 2017 Feb; 35(6):598-604. PubMed ID: 28199819
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hospital volume and short-term outcomes after cytoreductive nephrectomy.
    Xia L; Strother MC; Taylor BL; Chelluri RR; Pulido JE; Guzzo TJ
    J Surg Oncol; 2018 Jun; 117(7):1589-1596. PubMed ID: 29575038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of treatment center and hospital volume on survival for locally advanced cervical cancer.
    Wright JD; Huang Y; Ananth CV; Tergas AI; Duffy C; Deutsch I; Burke WM; Hou JY; Neugut AI; Hershman DL
    Gynecol Oncol; 2015 Dec; 139(3):506-12. PubMed ID: 26177552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.